Pharma BD Deal Intelligence

Tempus AI / Personalis, Inc.

2026 · Acquisition/Merger · $1.5B · Pending

Tempus AI entered a definitive merger agreement to acquire genomic diagnostics company Personalis in a transaction valued at approximately USD 1.5 billion, or USD 16.25 per Personalis share. Consideration is primarily Tempus Class A stock based on a formula tied to Tempus' volume-weighted average share price, with an option for Tempus to pay cash for up to half of the Personalis shares. The acquisition brings Personalis' NeXT Personal molecular residual disease assay into Tempus' AI-enabled precision oncology platform, extending it from diagnosis and therapy selection into recurrence monitoring. Closing is expected in late 2026 or early 2027 subject to Personalis shareholder approval and regulatory clearances.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals